decisionhealth Newsletters, Part B News - 2023 Issue 8 (August)
Accurately report JW, JZ modifiers before Oct. 1 enforcement
Subscribe or sign in to view the full article.
Article Overview
This article summarizes CMS guidance on the JW and JZ modifiers for Medicare Part B drug reporting. It is aimed at billing and coding professionals who need a high-level understanding of where the modifiers apply, the settings and provider types referenced by CMS, and the approaching enforcement timeline that affects claim processing.
Why This Topic Matters
The article matters because it highlights a Medicare billing requirement that can affect whether claims are processed correctly. It also points readers to CMS FAQs that clarify setting-specific reporting expectations and documentation considerations.
What You Will Learn
- The Medicare reporting context for JW and JZ modifiers
- Which care settings and provider types CMS discusses in relation to the modifiers
- The types of drugs and vaccines referenced in CMS guidance
- The significance of the upcoming enforcement date and claim-processing impact
- Where to find additional CMS guidance and documentation details
Who Should Read This
- Medical coders
- Billing staff
- Compliance teams
- Physician practice administrators
- Hospital outpatient billing professionals
- Pharmacy billing professionals
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com